TQB2450 + carboplatin + pemetrexed

TQB2450 + carboplatin + pemetrexed is a therapeutic **three-drug combination** used in oncology clinical trials, primarily for advanced stages of cancer including non-small cell lung cancer. - **TQB2450** (also known as benmelstobart) is a humanized monoclonal IgG1 antibody that targets **programmed cell death ligand 1 (PD-L1)**. It blocks PD-L1 interaction with PD-1 and CD80, thereby activating T cells and promoting antitumor immune responses[1][3][4]. - **Carboplatin** is a cytotoxic chemotherapy drug from the platinum agent class that inhibits DNA synthesis by forming DNA crosslinks, leading to apoptosis in rapidly dividing tumor cells. - **Pemetrexed** is a folate antimetabolite chemotherapy agent that disrupts folate-dependent biochemical processes essential for cell replication, inhibiting thymidylate synthase and other enzymes in the purine/pyrimidine synthesis pathways. This combination enhances cancer cell death through both immune-mediated mechanisms (via TQB2450) and direct cytotoxicity (via carboplatin and pemetrexed). It is being investigated in clinical trials, mainly for lung cancer and other solid malignancies.

Other names

benmelstobart + carboplatin + pemetrexed